Recent status of drug-induced liver injury

Hepatology Research

Volumn 39, Issue 1, 2009, Pages 1-6

  Takikawa, Hajime ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Diagnostic criteria; Diagnostic scale; Dietary supplement; Drug induced liver injury; Drug induced lymphocyte stimulation test

Indexed keywords

ALCOHOL; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; CARDIOVASCULAR AGENT; CHINESE DRUG; CORTICOSTEROID; GASTROINTESTINAL AGENT; HERBACEOUS AGENT; NEUROLEPTIC AGENT; PARACETAMOL; SULFONAMIDE;

AUTOIMMUNE HEPATITIS; CORTICOSTEROID THERAPY; DIET SUPPLEMENTATION; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG RESPONSE; EOSINOPHILIA; GENETIC SUSCEPTIBILITY; HEALTH SURVEY; HUMAN; INCIDENCE; JAPAN; LIVER BIOPSY; LIVER INJURY; LIVER TOXICITY; LYMPHOCYTE TRANSFORMATION TEST; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY;

EID: 58149179994     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2008.00400.x     Document Type: Review

References (60)

1. Nathwani RA, Kaplowitz N. Drug hepatotoxicity. Clin Liver Dis 2006; 10: 207-17.
2. Abboud CA, Kaplowitz H. Drug-induced liver injury. Drug Saf 2007; 30: 277-94.
3. Hussaini SH, Farrington EA. Idiosyncratic drug-induced liver injury: An overview. Expert Opin Drug Saf 2007; 6: 673-84.
4. Gunawan B, Kaplowitz N. Clinical perspectives on xenobiotic-induced hepatotoxicity. Drug Metab Rev 2004; 36: 201-12.
5. Stickel F, Patsenker E, Schuppan D. Herbal hepatotoxicity. J Hepatol 2005; 43: 901-10.
6. Takikawa H. Drug-induced liver injury by dietary supplements in Japan. Jpn Med Assoc J 2006; 49: 327-9.
7. Bleibel W, Kim S, D'Silva K. Drug-induced liver injury: Review article. Dig Dis Sci 2007; 52: 2463-71.
8. Uchida S, Kitami N. [Fundamental studies on the lymphocyte stimulation test in patients with drug-induced hepatic injury.] Kanzo 1989; 30: 439-43 (in Japanese).
9. Yokote Y, Fukami K, Tomita J, Tsuru M, Matsushita S, Fukazawa T. Clinical characteristics and dysfunction in lymphocyte stimulation test-positive elderly. Nippon Ronen Igakkai Zasshi 1992; 29: 469-74.
10. Kawasaki A, Mizushima Y, Kumatani H, Kitagawa M, Kobayashi M. A useful diagnostic method for drug-induced pneumonitis: A case report. Am J Chin Med 1994; 22: 329-36.
11. Mori H, Yamanaka K, Kaketa M etal. Drug eruption caused by azathioprine: value of using the drug-induced lymphocytes stimulation test for diagnosis. J Dermatol 2004; 31: 731-6.
12. Saito M, Yagi M, Uno K, Takanaka K. Comparative study of the usefulness of the drug-induced lymphocyte stimulation test and the leukocyte migration test in drug allergies. Biol Pharm Bull 2008; 31: 299-304.
13. Takikawa H, Takamori Y, Kumagi T et al. Assessment of 287 Japanese cases of drug induced liver injury by the diagnostic scale of the International Consensus Meeting. Hepatol Res 2003; 27: 92-5.
14. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005; 4: 489-99.
15. Hagiwara K, Sato T, Yamada H, Yamaguchi M, Akiyama O, Tomioka H. LST for methotrexate in patients with rheumatoid arthritis. Study show low specificity. Allergy Clin Immunol Int 2005; 17: 156-61.
16. Lee WM. Assessing causality in drug-induced liver injury. J Hepatol 2000; 33: 1003-5.
17. Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology 2001; 33: 308-10.
18. Bissell DM, Gores GJ, Laskin D, Hoofnagle JH. Drug-induced liver injury: Mechanisms and test systems. Hepatology 2001; 33: 1009-13.
19. Watanabe N, Takashimizu S, Kojima S et al. Clinical and pathological features of a prolonged type of acute intrahepatic cholestasis. Hepatol Res 2007; 37: 598-607.
20. Japan Society of Hepatology. [A proposal of diagnostic criteria of drug-induced liver injury.] Proceeding of the third Drug and Liver Meeting. Tokyo: Sharyo Publishing, 1978; 96-8 (in Japanese).
21. Danan G, Benichou C. Causality assessment of adverse reactions to drugs. I. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323-30.
22. Maria VAJ, Victorino RMM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997; 26: 664-9.
23. Consensus D. Meeting on: Causality assessment of drug-induced liver injury. J Hepatol 1988; 7: 132-6.
24. Benichou C. Criteria of drug-induced liver disorders. Report of an International Consensus Meeting. J Hepatol 1990; 11: 272-6.
25. Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs - II. An original model for validation of drug causality assessment methods: Case reports with positive rechallenge. J Clin Epidermol 1993; 11: 1331-6.
26. Aithal GP, Rawlins MD, Day CP. Clinical diagnostic scale: A useful tool in the evaluation of suspected hepatotoxic adverse drug reactions. J Hepatol 2000; 33: 949-52.
27. Lucena MI, Gamargo R, Andrade RJ, Perez-Sanchez CJ, Sanchez de la Cuesta F. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 2001; 33: 123-30.
28. Shapiro MA, Lewis JH. Causality assessment of drug-induced liver hepatotoxicity: Promises and pitfalls. Clin Liver Dis 2007; 11: 477-505.
29. Watanabe M, Shibuya A. Validity study of a new diagnostic scale for drug-induced liver injury in Japan - comparison with two previous scales. Hepatol Res 2004; 30: 148-54.
30. Takikawa H, Onji M. A proposal of the diagnostic scale of drug induced liver injury. Hepatol Res 2005; 2: 250-1.
31. Ayada M, Ishikawa T, Okumura A et al. [Cholestatic hepatic injury related to administration of sodium risedronate hydrate. A case report with distinctive histological findings.] Kanzo 2006; 47: 10-15 (in Japanese).
32. Watanabe M, Shibuya A, Miura Y et al. [Validity study of DDW-J 2004 scoring scale for drug-induced liver injury.] Kanzo 2007; 48: 219-26 (in Japanese).
33. Usui K, Oda Y, Kubota R et al. [Clinical application of the leukocyte migration test and new diagnostic criteria for identifying causative agents in patients with drug-induced liver injury.] Hepatogastroenterology 2007; 54: 1752-7.
34. Ayada M, Ishikawa T, Okumura A et al. [Management of inatinib mesilate-related hepatic injury by adjusting the dose of drug in a patient with chronic myelogenous leukemia: A case report.] Kanzo 2007; 48: 505-10 (in Japanese).
35. Larson AM, Polson J, Fontana RJ et al. Acetaminophen-induced acute liver failure: Results of a United States multicenter, prospective study. Hepatology 2005; 42: 1364-72.
36. Slatore CG, Tilles SA. Sulfonamide hypersensitivity. Immunol Allergy Clin North Am 2004; 24: 477-90.
37. Seeff LB, Cuccherini BA, Zimmerman HJ, Adler E, Benjamin SB. Acetaminophen hepatotoxicity in alcoholics. A therapeutic misadventure. Ann Intern Med 1986; 104: 399-404.
38. Wong WM, Wu PC, Yuen MF et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 2000; 31: 201-6.
39. Bonfanti P, Landonio S, Ricci E et al. Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27: 316-18.
40. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of hepatitis C and B infections. Hepatology 2002; 35: 182-9.
41. Lee BH, Koh WJ, Choi MS et al. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. Chest 2005; 127: 1304-11.
42. Bruno R, Sacchi P, Maiocchi L, Patruno S, Filice G. Hepatotoxicity and antiretroviral therapy with protease inhibitors: A review. Dig Liver Dis 2006; 38: 363-73.
43. Day CP. NAS H-related liver failure: One hit too many? Am J Gastroenterol 2002; 97: 1872-4.
44. Tarantino G, Conca P, Basile V et al. A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. Hepatol Res 2007; 37: 410-15.
45. Takikawa H, Onji M, Takamori Y et al. [Proposal of diagnostic criteria for drug-induced liver injury revised by the DDW-J 2004 Workshop.] Kanzo 2005; 486: 85-90 (in Japanese).
46. Kumagi T, Murata Y, Onji M. [Scope and limitation of new proposal criteria of "DDW-J 2004".] Clin Exp Med 2005; 214: 779-84 (in Japanese).
47. Takikawa H, Sakisaka S, Aiso M et al. [Recent status of drug-induced liver injury: An analysis of 366 cases between 2002 and 2006.] Kanzo 2007; 48: 517-21 (in Japanese).
48. Tameda T, Adachi Y, Watanabe A. [National survey of drug-induced liver injury.] In: Watanabe A, Higuchi K, eds. [Newest Hepatology.] Tokyo: Shinko-Igaku, 2001; 50-61 (in Japanese).
49. Wai CT, Tan BH, Chan CL et al. Drug-induced liver injury at an Asian center: A prospective study. Liver Int 2007; 27: 465-74.
50. Kim JB, Sohn JH, Lee HL et al. [Clinical characteristics of acute toxic liver injury.] Korean J Hepatol 2004; 10: 125-34 (in Korean).
51. Sgro C, Clinard F, Ouazir K et al. Incidence of drug-induced hepatic injuries: A French population-based study. Hepatology 2002; 36: 451-5.
52. Ibanez L, Perez E, Vidal X, Laporte JR; Grup d'Estudi Multicenteric d'Hepatotoxicitat Aguda de Barcelona (GEMHAB). Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: Epidemiological and clinical features, and exposure to drugs. J Hepatol 2002; 37: 592-600.
53. Andrade RJ, Lucena MI, Fernandez MC et al. Drug-induced liver injury: An analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512-21.
54. Lewis JD, Strom BL. Balancing safety of dietary supplements with the free market. Ann Intern Med 2002; 136: 616-18.
55. Larrey D, Vial T, Pauwels A et al. Hepatitis after germander (Teucrium chamaedrys) administration: Another instance of herbal medicine hepatotoxicity. Ann Intern Med 1992; 117: 129-32.
56. Favreau JT, Ryu ML, Braunstein G et al. Severe hepatotoxicity associated with the dietary supplement LipoKinetix. Ann Intern Med 2002; 136: 590-5.
57. Estes JD, Stolpman D, Olyaei A High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure. Arch Surg 2003; 138: 852-8.
58. Stickel F. Slimming at all costs: Herbalife-induced liver injury. J Hepatol 2007; 47: 444-6.
59. Schoepfer AM, Engel A, Fattinger K et al. Herbal does not mean innocuous: Ten cases of severe hepatotoxicity associated with dietary supplements from Herbalife products. J Hepatol 2007; 47521-6.
60. Fujii H, Takagaki N, Yoh T et al. Non-prescription supplement-induced hepatitis with hyperferritinemia and mutation (H63D) in the HFE gene. Hepatol Res 2008; 38: 319-23.